Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 3Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 76INDUSTRY 49NIH 22NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Head and Neck Neoplasms 1

Interventions

Cisplatin 24Radiotherapy 18Carboplatin 18Paclitaxel 17Vincristine 15Cyclophosphamide 14Etoposide 13Filgrastim 12Doxorubicin 12Gemcitabine 11Temozolomide 10Cytarabine 9Topotecan 8Docetaxel 8Methotrexate 7Irinotecan 7Granulocyte Colony-Stimulating Factor 7Dexamethasone 7Taxes 6Radiation 6Peripheral Blood Stem Cell Transplantation 6Radiotherapy, Conformal 5Oxaliplatin 5Melphalan 5Fenretinide 5Chemotherapy, Adjuvant 5Capecitabine 5etoposide phosphate 4Trastuzumab 4Platinum 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × NETWORK × Erlotinib Hydrochloride × Clear all
NCT00079053 2023-08-04

Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Canadian Cancer Trials Group

Phase 1 Completed
19 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡